Evidence map›Paper›PMID 41359666›Full record

ArticlePLoS pathogens2025

SAMD9L inhibits flavivirus translation independently of its capacity to trigger innate immune response.

Marion Cannac, Jim Zoladek, Inès Bribes, Mathis Fresneau-Resende, Alexandre Legrand, Rémi Demeure, Eva Zusinaite, Andres Merits, Lucie Etienne, Sébastien Nisole

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marion CannacInstitut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS UMR9004, INSERM, Montpellier, France.
Jim ZoladekInstitut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS UMR9004, INSERM, Montpellier, France.
Inès BribesInstitut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS UMR9004, INSERM, Montpellier, France.
Mathis Fresneau-ResendeInstitut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS UMR9004, INSERM, Montpellier, France.
Alexandre LegrandCentre international de recherche en infectiologie (CIRI), Inserm U1111, Université Claude-Bernard Lyon 1, CNRS UMR5308, École normale supérieure de Lyon, Lyon, France.
Rémi DemeureCentre international de recherche en infectiologie (CIRI), Inserm U1111, Université Claude-Bernard Lyon 1, CNRS UMR5308, École normale supérieure de Lyon, Lyon, France.
Eva ZusinaiteInstitute of Bioengineering, University of Tartu, Tartu, Estonia.
Andres MeritsInstitute of Bioengineering, University of Tartu, Tartu, Estonia.
Lucie EtienneCentre international de recherche en infectiologie (CIRI), Inserm U1111, Université Claude-Bernard Lyon 1, CNRS UMR5308, École normale supérieure de Lyon, Lyon, France.
Sébastien NisoleInstitut de Recherche en Infectiologie de Montpellier (IRIM), Univ Montpellier, CNRS UMR9004, INSERM, Montpellier, France.ORCID 0000-0001-9793-419X

Funding

Agence Nationale de la RechercheAgence Nationale de Recherches sur le SIDA et les Hépatites ViralesEuropean Virus Archive GLOBAL
6 · The paper itself

Abstract

Interferon-stimulated genes (ISGs) play a pivotal role in the innate immune response to viral infection. Among them, SAMD9 and its paralog SAMD9L have recently emerged as important antiviral effectors with translation-inhibitory activity. While both proteins restrict poxvirus, rotavirus and reovirus replication, only SAMD9L has been shown to inhibit HIV and other lentiviruses. In this study, we identify human SAMD9L as a potent and broad-spectrum restriction factor that targets multiple medically relevant flaviviruses, including West Nile virus (WNV), Zika virus (ZIKV), dengue virus (DENV), and Usutu virus (USUV). Exogenous expression of SAMD9L, but not SAMD9, efficiently suppressed replication of all tested flaviviruses. Furthermore, its knockdown in human myeloid cells, including microglial cells and primary macrophages, impaired the antiviral activity of type I interferon, identifying SAMD9L as a key antiviral ISG in primary target cells of flavivirus infection. Mechanistically, we demonstrate that SAMD9L inhibits viral replication by targeting the translation of flaviviral RNA, and that this activity depends on its Schlafen-like ribonuclease domain, previously implicated in the inhibition of HIV-1 translation. Interestingly, although SAMD9 does not inhibit flavivirus replication, it is able to repress the translation of flaviviral RNA outside the context of infection, suggesting that its activation may be virus-specific or that flaviviruses have evolved mechanisms to evade or counteract SAMD9's antiviral activity. Finally, we confirm that SAMD9 and SAMD9L overexpression induces activation of the innate immune response. However, this immunostimulatory function is dispensable for SAMD9L-mediated antiviral activity, since SAMD9L is able to restrict flavivirus replication independently of innate immune activation. Together, our findings broaden the known antiviral repertoire of SAMD9L, establish its essential role in restricting flavivirus replication via translational repression, and highlight its function as a key component of the cellular defenses against flaviviruses in myeloid cells.

Indexed as

FlavivirusFlavivirus InfectionsImmunity, InnateProtein BiosynthesisProteinsAnimalsHEK293 CellsHumansIntracellular Signaling Peptides and ProteinsVirus ReplicationIntracellular Signaling Peptides and ProteinsProteinsSAMD9 protein, human

Identifiers

PMID41359666
PMCPMC12698002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.